Table 2.
Subgroup analyses of comparison
| Subgroup on vaccine type | Pooled MD | Heterogeneity | ||
|---|---|---|---|---|
|
|
|
|||
| MD (95% CI) | P | I2 | P | |
| Total motility | ||||
| BNT162b2 | 0.11 (−0.79–1.01) | 0.81 | 0 | 0.38 |
| BNT162b2/mRNA-1273 | 2.12 (−5.08–9.32) | 0.56 | 84 | 0.01 |
| Inactivated | 1.52 (−2.50–5.54) | 0.46 | - | - |
| Sperm concentration | ||||
| BNT162b2 | 3.96 (−3.75–11.66) | 0.31 | 0 | 0.89 |
| BNT162b2/mRNA-1273 | 2.24 (−3.92–8.39) | 0.48 | 25 | 0.25 |
| Inactivated | 0.18 (−4.46–4.82) | 0.94 | - | - |
| Semen volume | ||||
| BNT162b2 | −0.13 (−0.52–0.26) | 0.51 | 0 | 0.68 |
| BNT162b2/mRNA-1273 | 0.27 (−0.15–0.69) | 0.21 | 57 | 0.13 |
| Inactivated | −0.13 (−0.42–0.16) | 0.38 | - | - |
MD: mean difference; CI: confidential interval; mRNA: messenger RNA; -: no value